(HLI) Houlihan Lokey - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4415931009
Stock: Mergers, Acquisitions, Restructuring, Valuation, Advisory
Total Rating 40
Risk 91
Buy Signal -0.89
| Risk 5d forecast | |
|---|---|
| Volatility | 28.9% |
| Relative Tail Risk | -3.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -29.71 |
| Character TTM | |
|---|---|
| Beta | 1.301 |
| Beta Downside | 0.889 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.90% |
| CAGR/Max DD | 0.67 |
EPS (Earnings per Share)
Revenue
Description: HLI Houlihan Lokey March 04, 2026
Houlihan Lokey, Inc. (HLI) is an investment banking firm offering M&A, capital markets, financial restructuring, and valuation advisory services globally. Investment banking is a relationship-driven business.
The company operates through three segments: Corporate Finance (CF), Financial Restructuring (FR), and Financial and Valuation Advisory (FVA).
The CF segment provides M&A advisory, debt and equity financing, and other corporate finance services. The FR segment advises on recapitalization and deleveraging transactions, including reorganization plans and liability management. The FVA segment delivers valuation services for various assets and liabilities, along with fairness and solvency opinions. These services are critical for corporate governance and transaction integrity.
HLI serves corporations, financial sponsors, and government agencies. Further research on platforms like ValueRay can provide deeper insights into HLIs financial performance and market position.
Headlines to watch out for
- M&A transaction volume directly impacts Corporate Finance revenue
- Financial restructuring activity drives segment performance
- Interest rate changes influence capital markets advisory demand
- Economic downturns increase demand for valuation advisory services
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 447.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA -0.74 > 1.0 |
| NWC/Revenue: 15.34% < 20% (prev 15.92%; Δ -0.59% < -1%) |
| CFO/TA 0.20 > 3% & CFO 769.5m > Net Income 447.8m |
| Net Debt (-62.2m) to EBITDA (667.9m): -0.09 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.4m) vs 12m ago -0.49% < -2% |
| Gross Margin: 37.26% > 18% (prev 0.38%; Δ 3688 % > 0.5%) |
| Asset Turnover: 71.45% > 50% (prev 64.55%; Δ 6.91% > 0%) |
| Interest Coverage Ratio: 15.51 > 6 (EBITDA TTM 667.9m / Interest Expense TTM 39.8m) |
Altman Z'' 4.11
| A: 0.10 (Total Current Assets 1.39b - Total Current Liabilities 988.8m) / Total Assets 3.94b |
| B: 0.40 (Retained Earnings 1.59b / Total Assets 3.94b) |
| C: 0.17 (EBIT TTM 617.9m / Avg Total Assets 3.71b) |
| D: 0.95 (Book Value of Equity 1.56b / Total Liabilities 1.64b) |
| Altman-Z'' Score: 4.11 = AA |
Beneish M -3.53
| DSRI: 0.48 (Receivables 210.9m/369.4m, Revenue 2.65b/2.24b) |
| GMI: 1.02 (GM 37.26% / 38.08%) |
| AQI: 0.76 (AQ_t 0.38 / AQ_t-1 0.50) |
| SGI: 1.18 (Revenue 2.65b / 2.24b) |
| TATA: -0.08 (NI 447.8m - CFO 769.5m) / TA 3.94b) |
| Beneish M-Score: -3.53 (Cap -4..+1) = AAA |
What is the price of HLI shares?
As of March 11, 2026, the stock is trading at USD 145.61 with a total of 722,736 shares traded.
Over the past week, the price has changed by -10.17%, over one month by -15.31%, over three months by -19.00% and over the past year by -4.42%.
Over the past week, the price has changed by -10.17%, over one month by -15.31%, over three months by -19.00% and over the past year by -4.42%.
Is HLI a buy, sell or hold?
Houlihan Lokey has received a consensus analysts rating of 3.44.
Therefor, it is recommend to hold HLI.
- StrongBuy: 2
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the HLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 206.4 | 41.7% |
| Analysts Target Price | 206.4 | 41.7% |
HLI Fundamental Data Overview March 11, 2026
P/E Trailing = 22.5831
P/E Forward = 16.5837
P/S = 3.8685
P/B = 4.4659
P/EG = 6.54
Revenue TTM = 2.65b USD
EBIT TTM = 617.9m USD
EBITDA TTM = 667.9m USD
Long Term Debt = 14.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 49.9m USD (from shortTermDebt, last fiscal year)
Debt = 994.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -62.2m USD (from netDebt column, last quarter)
Enterprise Value = 10.18b USD (10.24b + Debt 994.3m - CCE 1.06b)
Interest Coverage Ratio = 15.51 (Ebit TTM 617.9m / Interest Expense TTM 39.8m)
EV/FCF = 13.78x (Enterprise Value 10.18b / FCF TTM 738.9m)
FCF Yield = 7.26% (FCF TTM 738.9m / Enterprise Value 10.18b)
FCF Margin = 27.90% (FCF TTM 738.9m / Revenue TTM 2.65b)
Net Margin = 16.91% (Net Income TTM 447.8m / Revenue TTM 2.65b)
Gross Margin = 37.26% ((Revenue TTM 2.65b - Cost of Revenue TTM 1.66b) / Revenue TTM)
Gross Margin QoQ = 38.50% (prev 33.51%)
Tobins Q-Ratio = 2.59 (Enterprise Value 10.18b / Total Assets 3.94b)
Interest Expense / Debt = 0.47% (Interest Expense 4.68m / Debt 994.3m)
Taxrate = 31.30% (53.1m / 169.6m)
NOPAT = 424.5m (EBIT 617.9m * (1 - 31.30%))
Current Ratio = 1.41 (Total Current Assets 1.39b / Total Current Liabilities 988.8m)
Debt / Equity = 0.43 (Debt 994.3m / totalStockholderEquity, last quarter 2.29b)
Debt / EBITDA = -0.09 (Net Debt -62.2m / EBITDA 667.9m)
Debt / FCF = -0.08 (Net Debt -62.2m / FCF TTM 738.9m)
Total Stockholder Equity = 2.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.08% (Net Income 447.8m / Total Assets 3.94b)
RoE = 20.14% (Net Income TTM 447.8m / Total Stockholder Equity 2.22b)
RoCE = 27.61% (EBIT 617.9m / Capital Employed (Equity 2.22b + L.T.Debt 14.5m))
RoIC = 19.09% (NOPAT 424.5m / Invested Capital 2.22b)
WACC = 9.79% (E(10.24b)/V(11.24b) * Re(10.71%) + D(994.3m)/V(11.24b) * Rd(0.47%) * (1-Tc(0.31)))
Discount Rate = 10.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.40%
[DCF] Terminal Value 75.67% ; FCFF base≈714.6m ; Y1≈881.5m ; Y5≈1.50b
[DCF] Fair Price = 342.2 (EV 18.57b - Net Debt -62.2m = Equity 18.63b / Shares 54.5m; r=9.79% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 80.83 | EPS CAGR: 11.27% | SUE: 0.39 | # QB: 0
Revenue Correlation: 89.89 | Revenue CAGR: 11.85% | SUE: 0.94 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.09 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=9
EPS next Year (2027-03-31): EPS=8.84 | Chg7d=-0.001 | Chg30d=+0.084 | Revisions Net=-1 | Growth EPS=+11.1% | Growth Revenue=+12.8%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.3% (Discount Rate 10.7% - Earnings Yield 4.4%)
[Growth] Growth Spread = +6.6% (Analyst 12.8% - Implied 6.3%)
P/E Forward = 16.5837
P/S = 3.8685
P/B = 4.4659
P/EG = 6.54
Revenue TTM = 2.65b USD
EBIT TTM = 617.9m USD
EBITDA TTM = 667.9m USD
Long Term Debt = 14.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 49.9m USD (from shortTermDebt, last fiscal year)
Debt = 994.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -62.2m USD (from netDebt column, last quarter)
Enterprise Value = 10.18b USD (10.24b + Debt 994.3m - CCE 1.06b)
Interest Coverage Ratio = 15.51 (Ebit TTM 617.9m / Interest Expense TTM 39.8m)
EV/FCF = 13.78x (Enterprise Value 10.18b / FCF TTM 738.9m)
FCF Yield = 7.26% (FCF TTM 738.9m / Enterprise Value 10.18b)
FCF Margin = 27.90% (FCF TTM 738.9m / Revenue TTM 2.65b)
Net Margin = 16.91% (Net Income TTM 447.8m / Revenue TTM 2.65b)
Gross Margin = 37.26% ((Revenue TTM 2.65b - Cost of Revenue TTM 1.66b) / Revenue TTM)
Gross Margin QoQ = 38.50% (prev 33.51%)
Tobins Q-Ratio = 2.59 (Enterprise Value 10.18b / Total Assets 3.94b)
Interest Expense / Debt = 0.47% (Interest Expense 4.68m / Debt 994.3m)
Taxrate = 31.30% (53.1m / 169.6m)
NOPAT = 424.5m (EBIT 617.9m * (1 - 31.30%))
Current Ratio = 1.41 (Total Current Assets 1.39b / Total Current Liabilities 988.8m)
Debt / Equity = 0.43 (Debt 994.3m / totalStockholderEquity, last quarter 2.29b)
Debt / EBITDA = -0.09 (Net Debt -62.2m / EBITDA 667.9m)
Debt / FCF = -0.08 (Net Debt -62.2m / FCF TTM 738.9m)
Total Stockholder Equity = 2.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.08% (Net Income 447.8m / Total Assets 3.94b)
RoE = 20.14% (Net Income TTM 447.8m / Total Stockholder Equity 2.22b)
RoCE = 27.61% (EBIT 617.9m / Capital Employed (Equity 2.22b + L.T.Debt 14.5m))
RoIC = 19.09% (NOPAT 424.5m / Invested Capital 2.22b)
WACC = 9.79% (E(10.24b)/V(11.24b) * Re(10.71%) + D(994.3m)/V(11.24b) * Rd(0.47%) * (1-Tc(0.31)))
Discount Rate = 10.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.40%
[DCF] Terminal Value 75.67% ; FCFF base≈714.6m ; Y1≈881.5m ; Y5≈1.50b
[DCF] Fair Price = 342.2 (EV 18.57b - Net Debt -62.2m = Equity 18.63b / Shares 54.5m; r=9.79% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 80.83 | EPS CAGR: 11.27% | SUE: 0.39 | # QB: 0
Revenue Correlation: 89.89 | Revenue CAGR: 11.85% | SUE: 0.94 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.09 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=9
EPS next Year (2027-03-31): EPS=8.84 | Chg7d=-0.001 | Chg30d=+0.084 | Revisions Net=-1 | Growth EPS=+11.1% | Growth Revenue=+12.8%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.3% (Discount Rate 10.7% - Earnings Yield 4.4%)
[Growth] Growth Spread = +6.6% (Analyst 12.8% - Implied 6.3%)